ABSCF: AI 评分 55/100 — AI 分析 (4月 2026)

AB Science S.A. is a Paris-based pharmaceutical company specializing in protein kinase inhibitors for both human and veterinary medicine. With a focus on innovative treatments for severe diseases, the company is advancing its lead compound, masitinib, through multiple clinical trials.

Key Facts: AI Score: 55/100 Sector: Healthcare

公司概况

概要：

AB Science S.A. is a pharmaceutical innovator focused on developing protein kinase inhibitors, particularly masitinib, to address critical health challenges in oncology and neurology, positioning itself as a key player in the specialty drug market.

ABSCF是做什么的？

Founded in 2001 and headquartered in Paris, France, AB Science S.A. is a pharmaceutical company dedicated to the research, development, and marketing of protein kinase inhibitors for both human and veterinary applications. The company has carved a niche in the healthcare sector by focusing on innovative therapies for severe and often life-threatening conditions. Its lead compound, masitinib, is a tyrosine kinase inhibitor that is currently undergoing Phase III clinical trials for various cancers, including prostate and pancreatic cancer, as well as for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in a Phase II clinical trial for the treatment of COVID-19. Beyond masitinib, AB Science is also developing AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase II trials assessing the safety and efficacy of masitinib combined with isoquercetin for hospitalized COVID-19 patients. The company markets masitinib under the Masivet brand in Europe, demonstrating its commitment to addressing unmet medical needs in both human and veterinary medicine. With a workforce of 40 employees, AB Science is poised to leverage its innovative pipeline to capture significant market share in the specialty drug sector.

ABSCF的投资论点是什么？

AB Science S.A. presents a unique investment thesis driven by its innovative pipeline and strategic focus on protein kinase inhibitors. The company's lead compound, masitinib, is positioned in multiple Phase III trials, targeting significant markets in oncology and neurology, which could yield substantial revenue upon successful commercialization. With a market capitalization of $0.10 billion and a negative P/E ratio of -8.22, the company is currently undervalued, presenting an opportunity for growth as clinical trial results emerge. The ongoing development of AB8939 and AB20001 further diversifies its portfolio, potentially unlocking additional revenue streams. However, investors should remain cautious of the inherent risks associated with clinical trials, regulatory approvals, and market competition, particularly from established players in the specialty drug segment.

ABSCF在哪个行业运营？

The pharmaceutical industry, particularly the segment focused on specialty and generic drug manufacturing, is characterized by rapid innovation and significant investment in research and development. The global market for oncology drugs is projected to grow substantially, driven by increasing cancer prevalence and advancements in targeted therapies. AB Science S.A. is strategically positioned within this growth trajectory, with its focus on protein kinase inhibitors aligning with industry trends towards personalized medicine. The competitive landscape includes several peers such as ELEAF, ELTP, GLASF, HGYMF, and INRLF, each vying for market share in a sector that is expected to expand as new therapies emerge and regulatory environments evolve.

Drug Manufacturers - Specialty & Generic

Healthcare

ABSCF有哪些增长机遇？

Growth opportunity 1: The global oncology drug market is expected to reach $200 billion by 2025, with targeted therapies like masitinib playing a crucial role. AB Science's lead compound is currently in Phase III trials for prostate and pancreatic cancer, positioning the company to capture a significant share of this expanding market, particularly if clinical outcomes are favorable.
Growth opportunity 2: The increasing prevalence of neurodegenerative diseases, such as Alzheimer's and ALS, presents a substantial market opportunity for AB Science. With masitinib targeting these conditions, the company could tap into a market projected to grow at a CAGR of 7% over the next five years, enhancing its revenue potential as it advances through clinical trials.
Growth opportunity 3: The COVID-19 pandemic has accelerated the demand for effective treatments, and AB Science's ongoing Phase II trials for masitinib in COVID-19 patients could lead to a timely entry into this market. Given the global focus on pandemic preparedness, successful trial results could open new revenue streams and partnerships with health authorities.
Growth opportunity 4: The development of AB8939 for acute myeloid leukemia addresses a critical need in oncology, with the market for leukemia treatments expected to grow significantly. As AB Science progresses through clinical trials, it could establish itself as a key player in this therapeutic area, potentially leading to lucrative licensing agreements or partnerships.
Growth opportunity 5: The veterinary medicine market is also on the rise, with an increasing focus on pet health and wellness. By marketing masitinib under the Masivet brand in Europe, AB Science can leverage this trend, tapping into a growing segment that is expected to see continued growth as pet owners prioritize advanced medical treatments for their animals.

Market capitalization of $0.10 billion reflects the company's current valuation amidst a promising drug pipeline.
P/E ratio of -8.22 indicates the company is operating at a loss, typical for firms in the clinical trial phase.
Profit margin of -831.5% highlights the challenges in achieving profitability while investing heavily in R&D.
Gross margin of 110.1% suggests strong pricing power and potential for high profitability upon successful product launches.
Beta of 1.36 indicates higher volatility compared to the market, reflecting the risks associated with biotech investments.

ABSCF提供哪些产品和服务？

Research and develop protein kinase inhibitors for human and veterinary medicine.
Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
Market masitinib under the Masivet brand for veterinary applications in Europe.
Develop innovative therapies targeting severe diseases such as cancer and neurodegenerative disorders.
Collaborate with healthcare professionals and regulatory bodies to ensure compliance and successful product launches.
Engage in ongoing research to expand its pipeline of drug candidates.

ABSCF如何赚钱？

Revenue generation primarily through the commercialization of innovative pharmaceutical products.
Engagement in clinical trials to advance drug candidates towards regulatory approval.
Partnerships and collaborations with healthcare organizations to enhance market reach.
Focus on niche markets within oncology and neurology to maximize profitability.
Utilization of intellectual property rights to protect and monetize drug developments.

Healthcare providers and hospitals seeking innovative treatment options.
Veterinary clinics and pet owners looking for advanced medical solutions for animals.
Pharmaceutical distributors and wholesalers for drug distribution.
Regulatory agencies for compliance and approval processes.
Research institutions for collaboration on clinical studies.

Strong focus on niche therapeutic areas with high unmet medical needs.
Innovative drug pipeline with multiple candidates in advanced clinical trials.
Established brand presence in veterinary medicine with Masivet.
Intellectual property protections that safeguard its drug developments.
Expertise in navigating complex regulatory environments for drug approvals.

什么因素可能推动ABSCF股价上涨？

Upcoming: Results from Phase III clinical trials for masitinib in various cancers are expected to be released in the next 12 months.
Ongoing: The Phase II clinical trial for masitinib as a treatment for COVID-19 is currently underway, with results anticipated soon.
Upcoming: Potential partnerships or licensing agreements for masitinib could be announced as the company progresses through clinical trials.
Ongoing: Continued development of AB8939 for acute myeloid leukemia is in progress, with updates expected in the coming quarters.
Upcoming: Expansion of marketing efforts for the Masivet brand in Europe is planned to enhance market penetration.

ABSCF的主要风险是什么？

Potential: Clinical trial outcomes could be unfavorable, impacting drug approval and market entry.
Ongoing: Regulatory hurdles may delay the approval process for new drugs.
Potential: Competitive pressures from larger pharmaceutical companies could affect market share.
Ongoing: Financial instability due to negative profit margins may limit operational capacity.

ABSCF的核心优势是什么？

Innovative pipeline with multiple drug candidates in advanced clinical trials.
Strong gross margin of 110.1%, indicating potential for high profitability.
Established brand presence in the veterinary market with Masivet.
Expertise in protein kinase inhibitors, a growing therapeutic area.

ABSCF的劣势是什么？

Negative profit margin of -831.5%, reflecting current operational challenges.
Limited financial resources with a market cap of only $0.10 billion.
Dependence on successful clinical trial outcomes for future revenue.
Small workforce of 40 employees may limit operational capacity.

ABSCF有哪些机遇？

Expanding global oncology market projected to reach $200 billion by 2025.
Growing demand for treatments targeting neurodegenerative diseases.
Potential for lucrative partnerships in the COVID-19 treatment space.
Increasing focus on veterinary medicine and pet health.

ABSCF面临哪些威胁？

Intense competition from established pharmaceutical companies in the oncology and neurology sectors.
Regulatory hurdles that could delay drug approvals and market entry.
Market volatility and investor sentiment impacting stock performance.
Risks associated with clinical trial failures and safety concerns.

ABSCF的竞争对手是谁？

Elephant Talk Communications — Focuses on telecommunications but competes in healthcare technology. — (ELEAF)
Elite Pharmaceuticals — Specializes in the development of generic and specialty pharmaceuticals. — (ELTP)
Glasgow Pharmaceuticals — Engaged in the development of specialty drugs. — (GLASF)
Hagerty — Diversified services but competes in healthcare segments. — (HGYMF)
Inovio Pharmaceuticals — Focuses on DNA medicines and competes in the oncology space. — (INRLF)

Key Metrics

MoonshotScore: 55/100

Company Profile

CEO: Alain Moussy
Headquarters: Paris, FR
Employees: 40
Founded: 2011

AI Insight

AI analysis pending for ABSCF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does AB Science S.A. do?

AB Science S.A. is a pharmaceutical company focused on the research, development, and marketing of protein kinase inhibitors. Its lead product, masitinib, is undergoing clinical trials for various severe diseases, including cancer and neurodegenerative disorders, as well as for veterinary applications.

What do analysts say about ABSCF stock?

Analysts focus on AB Science S.A.'s innovative pipeline, particularly the potential of masitinib in oncology and neurology. While the company faces challenges with profitability and market competition, its advanced clinical trials position it for potential growth, making it a subject of interest among biotech investors.

What are the main risks for ABSCF?

AB Science S.A. faces several risks, including the potential for unfavorable clinical trial results that could hinder drug approvals. Regulatory challenges may also delay market entry, and the company must navigate intense competition from established pharmaceutical firms, all of which could impact its financial stability and market position.